SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65, maverick1856
Search This Board:
Last Post: 7/3/2015 7:44:28 AM - Followers: 162 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Securities Registration Statement (simplified Form) (s-3) 07/02/2015 08:24:30 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/01/2015 05:32:41 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/01/2015 05:22:42 PM
CVM News: Initial Statement of Beneficial Ownership (3) 07/01/2015 05:17:30 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/01/2015 05:12:45 PM
PostSubject
#6818  Sticky Note CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6737  Sticky Note And then there were 20,.... drkazmd65 02/19/15 11:36:47 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#7156   Ahhh...new filing to cover $75 million more potential dilution Foxwoods Man 07/03/15 07:44:28 AM
#7155   Solid movement this week. trickledownfacists 07/02/15 10:31:11 AM
#7154   I don't get it either. Possibly it because hogg 07/02/15 06:03:53 AM
#7153   The monatary award if granted will help the Foxwoods Man 07/01/15 09:13:15 PM
#7152   The numbers seem like they should be picking trickledownfacists 07/01/15 07:39:47 PM
#7151   These enrollment numbers just defy logic....more is not Foxwoods Man 07/01/15 06:53:19 PM
#7150   inVentiv and CEL-SCI are locked in a legal trickledownfacists 07/01/15 05:03:23 PM
#7149   CEL-SCI Reports June Patient Enrollment in Its Phase trickledownfacists 07/01/15 04:59:57 PM
#7148   Any thoughts on if the $50 million payout trickledownfacists 07/01/15 04:10:34 PM
#7147   Over halfway to 800 patients. Lawsuit news trickledownfacists 07/01/15 03:52:46 PM
#7146   Perfect..decreased to 25 enrolled. Seems like as more centers Foxwoods Man 07/01/15 10:48:27 AM
#7145   stockcharts.com/c-sc/sc?s=CVM&p=D&b=3&g=0&i=p28263862263&r=1352978793335[ mick 06/30/15 05:44:38 PM
#7144   I agree with you FM, it's as if tprosuper 06/30/15 03:56:16 PM
#7143   I'll go with the 30 number...but...consider it stagnation Foxwoods Man 06/30/15 09:53:49 AM
#7142   OK,.... we saw a drop in patient enrollment drkazmd65 06/29/15 11:00:47 AM
#7141   I had thought 68 cents was a pretty sab63090 06/25/15 04:44:03 PM
#7140   So - did a bit of checking today drkazmd65 06/25/15 12:19:35 PM
#7139   stockcharts.com/c-sc/sc?s=CVM&p=D&yr=0&mn=2&dy=0&i=t21771599565&r=1392585 mick 06/20/15 03:14:35 PM
#7138   I've been apart of a medical trial. EVERYTHING Turney 06/15/15 05:35:04 AM
#7137   Paleman, thanks much for the offer; it would etpa 06/14/15 04:46:31 PM
#7136   Wonder if we will get any intermediate updates pijoe 06/14/15 03:02:49 PM
#7135   Just curious. With the annual meeting coming Paleman 06/14/15 02:26:41 PM
#7134   Cel-Sci Corp. Common (CVM) mick 06/10/15 05:23:34 PM
#7133   Yes I know what your point was I pijoe 06/06/15 09:56:24 PM
#7132   The point is that many patients ARE getting Foxwoods Man 06/06/15 01:18:29 PM
#7131   Soooo maybe more people should get cancer then pijoe 06/06/15 09:38:07 AM
#7130   Yep,.... it has become readily apparent that the drkazmd65 06/02/15 05:02:46 PM
#7129   Ok...I did listen to Geert's latest presentation...same stuff Foxwoods Man 06/01/15 04:20:05 PM
#7127   Maybe Geert can sue the current CRO too ducruacuteo11 06/01/15 11:47:09 AM
#7126   Five less patients last month...perfect. Foxwoods Man 06/01/15 11:17:43 AM
#7125   Also, Immunotherapy with the anti-PD-1 antibody pembrolizumab decreased the eddie51 05/30/15 08:15:32 PM
#7124   Cel-Sci Corp. Common (CVM) mick 05/30/15 11:27:55 AM
#7123   I saw a similar (or the same) AP Foxwoods Man 05/30/15 09:13:05 AM
#7122   Headline article in today's Houston Chronicle,"Immunotherapy drug aids Turney 05/30/15 08:29:46 AM
#7121   Well, I been checking in here off and sab63090 05/29/15 09:59:41 AM
#7120   Did Geert sell a lot of shares on Foxwoods Man 05/29/15 09:47:48 AM
#7119   Since warrants were attached "for free" and for sab63090 05/29/15 09:24:18 AM
#7118   So they closed for $16 million...minus the commissions Foxwoods Man 05/29/15 08:42:00 AM
#7117   Cel-Sci Corp. Common (CVM) mick 05/27/15 05:46:18 PM
#7116   I hear you loud and clear. I ducruacuteo11 05/26/15 05:22:44 PM
#7115   and if, we still believe that it will Foxwoods Man 05/26/15 04:32:33 PM
#7114   At this point, yes, you are right. ducruacuteo11 05/26/15 03:51:02 PM
#7113   At this price I think the better play Foxwoods Man 05/26/15 01:55:10 PM
#7112   Call me nuts but bought more @ .72 today Turney 05/26/15 01:37:04 PM
#7111   Not very long! Two quarters max. ducruacuteo11 05/26/15 12:52:54 PM
#7110   So how long will 14.8 million last (minus Foxwoods Man 05/26/15 07:36:01 AM
#7109   Ok...inquiring minds need to know... Foxwoods Man 05/24/15 08:12:24 AM
#7108   Cel-Sci Corp. Common (CVM) mick 05/24/15 12:48:50 AM
#7107   Geert will get his million $ back with Foxwoods Man 05/23/15 01:46:58 PM
#7106   The warrants do NOT have a market, but sab63090 05/23/15 11:49:30 AM
PostSubject